Skip to main content
Top
Published in: European Journal of Epidemiology 8/2010

01-08-2010 | PEDIATRIC EPIDEMIOLOGY

Fewer infants than older patients in paediatric randomised controlled trials

Authors: François Angoulvant, Florentia Kaguelidou, Stephane Dauger, Corinne Alberti

Published in: European Journal of Epidemiology | Issue 8/2010

Login to get access

Abstract

To determine whether the youngest age groups are less likely to be included in paediatric randomised controlled trials (PRCTs) than older children, we conducted a PubMed search using the keyword “randomised controlled trial” and the limit “all child: 0–18 years”. We retrieved 417 articles published in 2006 in 34 leading journals classified as general medical journals, paediatric medical journals, or specialist medical journals. We arbitrarily selected 144 articles, at random. For each study, we evaluated population age characteristics (central tendency, range, and dispersion), study design, sample size and topic. Of the 144 studies, only 82 were first reports of paediatric randomised controlled trials (PRCTs). Among the other studies, many were done in adults. Of the 82 PRCTs, only 11% included newborns and 26% infants; 59% included children and 39% adolescents. Using the same search strategy to retrieve PRCTs in the same journals in the last 4 months of 2009 retrieved 66 PRCTs, of which 17% included newborns, 24% infants, 61% children and 55% adolescents. The three health conditions most often reported were respiratory diseases, infectious diseases, and mental and behavioural disorders. In 34 leading journals, PRCTs were significantly less likely to include newborns and infants than older paediatric patients. Given the huge impact of PRCTs on paediatric health, additional efforts are needed to promote studies in newborns and infants, as well as studies of the impact of recent European and American regulations designed to encourage paediatric drug trials.
Literature
1.
go back to reference O’Leary M, Krailo M, Anderson JR, Reaman GH. Progress in childhood cancer: 50 years of research collaboration, a report from the Children’s Oncology Group. Semin Oncol. 2008;35:484–93.CrossRefPubMed O’Leary M, Krailo M, Anderson JR, Reaman GH. Progress in childhood cancer: 50 years of research collaboration, a report from the Children’s Oncology Group. Semin Oncol. 2008;35:484–93.CrossRefPubMed
2.
go back to reference Caldwell PH, Murphy SB, Butow PN, Craig JC. Clinical trials in children. Lancet. 2004;364:803–11.CrossRefPubMed Caldwell PH, Murphy SB, Butow PN, Craig JC. Clinical trials in children. Lancet. 2004;364:803–11.CrossRefPubMed
3.
go back to reference Conroy S, Choonara I, Impicciatore P, Mohn A, Arnell H, Rane A, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. BMJ. 2000;320:79–82.CrossRefPubMed Conroy S, Choonara I, Impicciatore P, Mohn A, Arnell H, Rane A, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. BMJ. 2000;320:79–82.CrossRefPubMed
4.
go back to reference Rakhmanina NY, van den Anker JN. Pharmacological research in pediatrics: from neonates to adolescents. Adv Drug Deliv Rev. 2006;58:4–14.CrossRefPubMed Rakhmanina NY, van den Anker JN. Pharmacological research in pediatrics: from neonates to adolescents. Adv Drug Deliv Rev. 2006;58:4–14.CrossRefPubMed
5.
go back to reference Shah SS, Hall M, Goodman DM, Feuer P, Sharma V, Fargason C Jr, et al. Off-label drug use in hospitalized children. Arch Pediatr Adolesc Med. 2007;161:282–90.CrossRefPubMed Shah SS, Hall M, Goodman DM, Feuer P, Sharma V, Fargason C Jr, et al. Off-label drug use in hospitalized children. Arch Pediatr Adolesc Med. 2007;161:282–90.CrossRefPubMed
6.
go back to reference Wilson JT. An update on the therapeutic orphan. Pediatrics. 1999;104:585–90.PubMed Wilson JT. An update on the therapeutic orphan. Pediatrics. 1999;104:585–90.PubMed
7.
go back to reference Salazar JC. Pediatric clinical trial experience: government, child, parent and physician’s perspective. Pediatr Infect Dis J. 2003;22:1124–7.CrossRefPubMed Salazar JC. Pediatric clinical trial experience: government, child, parent and physician’s perspective. Pediatr Infect Dis J. 2003;22:1124–7.CrossRefPubMed
8.
go back to reference Best Pharmaceuticals for Children Act. 107th Cong (January 4, 2002) ed. Best Pharmaceuticals for Children Act. 107th Cong (January 4, 2002) ed.
9.
go back to reference Better Medicines for Children—proposed regulatory actions in paediatric medicinal products. Brussels: European Commission; 2002. Better Medicines for Children—proposed regulatory actions in paediatric medicinal products. Brussels: European Commission; 2002.
10.
go back to reference AAMC. Principles for protecting integrity in the conduct and reporting of clinical trials. Approved by AAMC Executive Committee; 2005. AAMC. Principles for protecting integrity in the conduct and reporting of clinical trials. Approved by AAMC Executive Committee; 2005.
11.
go back to reference Martinez-Castaldi C, Silverstein M, Bauchner H. Child versus adult research: the gap in high-quality study design. Pediatrics. 2008;122:52–7.CrossRefPubMed Martinez-Castaldi C, Silverstein M, Bauchner H. Child versus adult research: the gap in high-quality study design. Pediatrics. 2008;122:52–7.CrossRefPubMed
12.
go back to reference Klassen TP, Hartling L, Craig JC, Offringa M. Children are not just small adults: the urgent need for high-quality trial evidence in children. PLoS Med. 2008;5:e172.CrossRefPubMed Klassen TP, Hartling L, Craig JC, Offringa M. Children are not just small adults: the urgent need for high-quality trial evidence in children. PLoS Med. 2008;5:e172.CrossRefPubMed
13.
go back to reference Cohen E, Goldman RD, Ragone A, Uleryk E, Atenafu EG, Siddiqui U, et al. Child vs adult randomized controlled trials in specialist journals: a citation analysis of trends, 1985–2005. Arch Pediatr Adolesc Med. 2010;164:283–8.CrossRefPubMed Cohen E, Goldman RD, Ragone A, Uleryk E, Atenafu EG, Siddiqui U, et al. Child vs adult randomized controlled trials in specialist journals: a citation analysis of trends, 1985–2005. Arch Pediatr Adolesc Med. 2010;164:283–8.CrossRefPubMed
14.
go back to reference Rheims S, Cucherat M, Arzimanoglou A, Ryvlin P. Greater response to placebo in children than in adults: a systematic review and meta-analysis in drug-resistant partial epilepsy. PLoS Med. 2008;5:e166.CrossRefPubMed Rheims S, Cucherat M, Arzimanoglou A, Ryvlin P. Greater response to placebo in children than in adults: a systematic review and meta-analysis in drug-resistant partial epilepsy. PLoS Med. 2008;5:e166.CrossRefPubMed
15.
go back to reference EMEA. Note for guidance on clinical investigation of medicinal products in the paediatric population (E11): the international conference on harmonisation of technical requirements for registration of pharmaceuticals for human use; 2002. EMEA. Note for guidance on clinical investigation of medicinal products in the paediatric population (E11): the international conference on harmonisation of technical requirements for registration of pharmaceuticals for human use; 2002.
16.
go back to reference ICH. U.S. Department of Health. FDA. Guidance for Industry E11 Clinical investigation of medicinal products in the Pediatric Population. The international conference on harmonisation of technical requirements for registration of pharmaceuticals for human use; 2000. ICH. U.S. Department of Health. FDA. Guidance for Industry E11 Clinical investigation of medicinal products in the Pediatric Population. The international conference on harmonisation of technical requirements for registration of pharmaceuticals for human use; 2000.
17.
go back to reference Rivara FP, Alexander D. Randomized controlled trials and pediatric research. Arch Pediatr Adolesc Med. 2010;164:296–7.CrossRefPubMed Rivara FP, Alexander D. Randomized controlled trials and pediatric research. Arch Pediatr Adolesc Med. 2010;164:296–7.CrossRefPubMed
19.
go back to reference Lee KP, Schotland M, Bacchetti P, Bero LA. Association of journal quality indicators with methodological quality of clinical research articles. Jama. 2002;287:2805–8.CrossRefPubMed Lee KP, Schotland M, Bacchetti P, Bero LA. Association of journal quality indicators with methodological quality of clinical research articles. Jama. 2002;287:2805–8.CrossRefPubMed
20.
go back to reference Gow RM, Barrowman NJ, Lai L, Moher D. A review of five cardiology journals found that observer variability of measured variables was infrequently reported. J Clin Epidemiol. 2008;61:394–401.CrossRefPubMed Gow RM, Barrowman NJ, Lai L, Moher D. A review of five cardiology journals found that observer variability of measured variables was infrequently reported. J Clin Epidemiol. 2008;61:394–401.CrossRefPubMed
22.
go back to reference Johnson TN. The development of drug metabolising enzymes and their influence on the susceptibility to adverse drug reactions in children. Toxicology. 2003;192:37–48.CrossRefPubMed Johnson TN. The development of drug metabolising enzymes and their influence on the susceptibility to adverse drug reactions in children. Toxicology. 2003;192:37–48.CrossRefPubMed
23.
go back to reference Weiss CF, Glazko AJ, Weston JK. Chloramphenicol in the newborn infant. A physiologic explanation of its toxicity when given in excessive doses. N Engl J Med. 1960;262:787–94.CrossRefPubMed Weiss CF, Glazko AJ, Weston JK. Chloramphenicol in the newborn infant. A physiologic explanation of its toxicity when given in excessive doses. N Engl J Med. 1960;262:787–94.CrossRefPubMed
24.
go back to reference 't Jong GW, Eland IA, Sturkenboom MC, van den Anker JN, Strickerf BH. Unlicensed and off-label prescription of respiratory drugs to children. Eur Respir J. 2004;23:310–3.CrossRefPubMed 't Jong GW, Eland IA, Sturkenboom MC, van den Anker JN, Strickerf BH. Unlicensed and off-label prescription of respiratory drugs to children. Eur Respir J. 2004;23:310–3.CrossRefPubMed
25.
go back to reference Schirm E, Tobi H, den Berg LT. Risk factors for unlicensed and off-label drug use in children outside the hospital. Pediatrics. 2003;111:291–5.CrossRefPubMed Schirm E, Tobi H, den Berg LT. Risk factors for unlicensed and off-label drug use in children outside the hospital. Pediatrics. 2003;111:291–5.CrossRefPubMed
26.
go back to reference Barr J, Brenner-Zada G, Heiman E, Pareth G, Bulkowstein M, Greenberg R, et al. Unlicensed and off-label medication use in a neonatal intensive care unit: a prospective study. Am J Perinatol. 2002;19:67–72.CrossRefPubMed Barr J, Brenner-Zada G, Heiman E, Pareth G, Bulkowstein M, Greenberg R, et al. Unlicensed and off-label medication use in a neonatal intensive care unit: a prospective study. Am J Perinatol. 2002;19:67–72.CrossRefPubMed
27.
go back to reference Freid VM, Makuc DM, Rooks RN. Ambulatory health care visits by children: principal diagnosis and place of visit. Vital Health Stat. 1998:1–23. Freid VM, Makuc DM, Rooks RN. Ambulatory health care visits by children: principal diagnosis and place of visit. Vital Health Stat. 1998:1–23.
28.
go back to reference Akinbami LJ, Moorman JE, Garbe PL, Sondik EJ. Status of childhood asthma in the United States, 1980–2007. Pediatrics. 2009;123(Suppl 3):S1:31–45. Akinbami LJ, Moorman JE, Garbe PL, Sondik EJ. Status of childhood asthma in the United States, 1980–2007. Pediatrics. 2009;123(Suppl 3):S1:31–45.
29.
go back to reference DeFrances CJ, Cullen KA, Kozak LJ. National Hospital Discharge Survey: 2005 annual summary with detailed diagnosis and procedure data. Vital Health Stat. 2007:1–209. DeFrances CJ, Cullen KA, Kozak LJ. National Hospital Discharge Survey: 2005 annual summary with detailed diagnosis and procedure data. Vital Health Stat. 2007:1–209.
30.
go back to reference Van Cleave J, Gortmaker SL, Perrin JM. Dynamics of obesity and chronic health conditions among children and youth. Jama. 2010;303:623–30.CrossRefPubMed Van Cleave J, Gortmaker SL, Perrin JM. Dynamics of obesity and chronic health conditions among children and youth. Jama. 2010;303:623–30.CrossRefPubMed
31.
go back to reference WHO. Global health risks: mortality and burden of disease attributable to selected major risks; 2009. WHO. Global health risks: mortality and burden of disease attributable to selected major risks; 2009.
32.
go back to reference Anand KJ, Aranda JV, Berde CB, Buckman S, Capparelli EV, Carlo W, et al. Summary proceedings from the neonatal pain-control group. Pediatrics. 2006;117:S9–22.CrossRefPubMed Anand KJ, Aranda JV, Berde CB, Buckman S, Capparelli EV, Carlo W, et al. Summary proceedings from the neonatal pain-control group. Pediatrics. 2006;117:S9–22.CrossRefPubMed
33.
go back to reference Benjamin DK Jr, Smith PB, Murphy MD, Roberts R, Mathis L, Avant D, et al. Peer-reviewed publication of clinical trials completed for pediatric exclusivity. Jama. 2006;296:1266–73.CrossRefPubMed Benjamin DK Jr, Smith PB, Murphy MD, Roberts R, Mathis L, Avant D, et al. Peer-reviewed publication of clinical trials completed for pediatric exclusivity. Jama. 2006;296:1266–73.CrossRefPubMed
35.
go back to reference Ward RM, Lane RH, Albertine KH. Basic and translational research in neonatal pharmacology. J Perinatol. 2006;26(Suppl 2):S8–12.CrossRefPubMed Ward RM, Lane RH, Albertine KH. Basic and translational research in neonatal pharmacology. J Perinatol. 2006;26(Suppl 2):S8–12.CrossRefPubMed
36.
go back to reference de Wildt SN, Ito S, Koren G. Challenges for drug studies in children: CYP3A phenotyping as example. Drug Discov Today. 2009;14:6–15.CrossRefPubMed de Wildt SN, Ito S, Koren G. Challenges for drug studies in children: CYP3A phenotyping as example. Drug Discov Today. 2009;14:6–15.CrossRefPubMed
37.
go back to reference Thingvoll ES, Guillet R, Caserta M, Dicenzo R. Observational trial of a 48-hour gentamicin dosing regimen derived from Monte Carlo simulations in infants born at less than 28 weeks’ gestation. J Pediatr. 2008;153:530–4.CrossRefPubMed Thingvoll ES, Guillet R, Caserta M, Dicenzo R. Observational trial of a 48-hour gentamicin dosing regimen derived from Monte Carlo simulations in infants born at less than 28 weeks’ gestation. J Pediatr. 2008;153:530–4.CrossRefPubMed
38.
go back to reference Politis P. Transition from the carrot to the stick: the evolution of pharmaceutical regulations concerning pediatric drug testing. Widener Law Rev. 2005;12:271. Politis P. Transition from the carrot to the stick: the evolution of pharmaceutical regulations concerning pediatric drug testing. Widener Law Rev. 2005;12:271.
39.
go back to reference Li JS, Eisenstein EL, Grabowski HG, Reid ED, Mangum B, Schulman KA, et al. Economic return of clinical trials performed under the pediatric exclusivity program. Jama. 2007;297:480–8.CrossRefPubMed Li JS, Eisenstein EL, Grabowski HG, Reid ED, Mangum B, Schulman KA, et al. Economic return of clinical trials performed under the pediatric exclusivity program. Jama. 2007;297:480–8.CrossRefPubMed
40.
go back to reference Lozano P, Sullivan SD, Smith DH, Weiss KB. The economic burden of asthma in US children: estimates from the National Medical Expenditure Survey. J Allergy Clin Immunol. 1999;104:957–63.CrossRefPubMed Lozano P, Sullivan SD, Smith DH, Weiss KB. The economic burden of asthma in US children: estimates from the National Medical Expenditure Survey. J Allergy Clin Immunol. 1999;104:957–63.CrossRefPubMed
41.
go back to reference Stevens CA, Turner D, Kuehni CE, Couriel JM, Silverman M. The economic impact of preschool asthma and wheeze. Eur Respir J. 2003;21:1000–6.CrossRefPubMed Stevens CA, Turner D, Kuehni CE, Couriel JM, Silverman M. The economic impact of preschool asthma and wheeze. Eur Respir J. 2003;21:1000–6.CrossRefPubMed
42.
go back to reference Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. Jama. 1996;276:637–9.CrossRefPubMed Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. Jama. 1996;276:637–9.CrossRefPubMed
Metadata
Title
Fewer infants than older patients in paediatric randomised controlled trials
Authors
François Angoulvant
Florentia Kaguelidou
Stephane Dauger
Corinne Alberti
Publication date
01-08-2010
Publisher
Springer Netherlands
Published in
European Journal of Epidemiology / Issue 8/2010
Print ISSN: 0393-2990
Electronic ISSN: 1573-7284
DOI
https://doi.org/10.1007/s10654-010-9480-2

Other articles of this Issue 8/2010

European Journal of Epidemiology 8/2010 Go to the issue